The global liquid biopsy market is expected to reach USD 7,429.32 million by 2031 from USD 2,309.91 million in 2023, growing at a CAGR of 16.8% during the forecast period of 2024 to 2031.
Market Segmentation
Global Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, and Services & Software), Biomarker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample Based, Urine Sample Based, Saliva & Other Tissue Fluid Sample-Based, Fecal Based Sampling, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.
Overview of Global Liquid Biopsy Market Dynamics
- Driver
- Growing demand for non-invasive liquid biopsy technique
- Restraint
- High cost of liquid biopsy test
- Opportunity
- Integration of artificial intelligence (AI) and machine learning
Market Players
Some of the major market players operating in the global liquid biopsy market are:
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- BIOCEPT, INC.
- Bio-Rad Laboratories, Inc.
- Exact Science Corporation
- Menarini Silicon Biosystems
- Epic Sciences
- NeoGenomics Laboratories
- mdxhealth
- F. Hoffmann-La Roche Ltd
- QIAGEN
- Oncocyte Corporation
- Johnson & Johnson Services, Inc.
- PathAI
- Fluxion Biosciences Inc.
- Guardant Health
- Laboratory Corporation of America Holdings
- ANGLE plc
- Natera, Inc.
- Sysmex Inostics Inc., (Subsidiary of Sysmex Corporation)
- STRECK
- Predicine
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 OVERVIEW OF THE GLOBAL LIQUID BIOPSY MARKET
- 1.4 LIMITATIONS
- 1.5 MARKETS COVERED
2 MARKET SEGMENTATION
- 2.1 MARKETS COVERED
- 2.2 GEOGRAPHICAL SCOPE
- 2.3 YEARS CONSIDERED FOR THE STUDY
- 2.4 CURRENCY AND PRICING
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL
- 2.6 MULTIVARIATE MODELLING
- 2.7 PRODUCT TYPE LIFELINE CURVE
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.9 DBMR MARKET POSITION GRID
- 2.10 MARKET TESTING TYPE COVERAGE GRID
- 2.11 VENDOR SHARE ANALYSIS
- 2.12 SECONDARY SOURCES
- 2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 PESTAL ANALYSIS
- 4.2 PORTER FIVE FORCES MODEL
5 GLOBAL LIQUID BIOPSY MARKET, REGULATION
- 5.1 REGULATION IN THE U.S.
- 5.2 REGULATION IN THE CANADA
5.3 REGULATION IN EUROPE:
5.4 REGULATIONS IN CHINA:
5.5 REGULATIONS IN JAPAN:
5.6 REGULATIONS IN INDIA:
5.7 REGULATIONS IN CANADA:
5.8 REGULATIONS IN AUSTRALIA:
5.9 REGULATIONS IN SOUTH AFRICA:
5.10 REGULATIONS IN SAUDI ARABIA:
6 MARKET OVERVIEW
- 6.1 DRIVERS
- 6.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE
- 6.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY
- 6.1.3 INCREASING CANCER PREVALENCE AND AWARENESS
- 6.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS
- 6.2 RESTRAINTS
- 6.2.1 HIGH COST OF LIQUID BIOPSY TESTS
- 6.2.2 LACK OF STANDARDIZED GUIDELINES
- 6.3 OPPORTUNITIES
- 6.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING
- 6.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY
- 6.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES
- 6.4 CHALLENGES
- 6.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY
- 6.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES
7 GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT
- 7.1 OVERVIEW
- 7.2 CONSUMABLES & ACCESSORIES
- 7.2.1 TEST KITS
- 7.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT
- 7.2.1.2 DNA ISOLATION KIT
- 7.2.1.3 OTHERS
- 7.2.2 COLLECTION TUBES
- 7.2.2.1 PIECES
- 7.2.2.2 PIECES
- 7.2.3 ASSAYS
- 7.2.3.1 FLEXIBLE REAGENTS
- 7.2.3.2 SCALABLE REAGENTS
- 7.2.3.3 OTHERS
- 7.2.4 CONTROL KIT
- 7.2.5 OTHERS
- 7.3 INSTRUMENTS
- 7.3.1 ANALYZERS
- 7.3.2 SYSTEMS
- 7.3.3 OTHERS
-
- 7.4 SERVICES & SOFTWARE
- 7.4.1 NGS ANALYSIS AND REPORTING SOFTWARE
- 7.4.2 DPCR ANALYSIS SOFTWARE
- 7.4.3 CASTPCR ANALYSIS SOFTWARE
- 7.4.4 OTHERS
8 GLOBAL LIQUID BIOPSY MARKET, BY BIOMAKER TYPE
- 8.1 OVERVIEW
- 8.2 CIRCULATING TUMOR CELLS (CTC'S)
- 8.2.1 CONSUMABLES & ACCESSORIES
- 8.2.2 INSTRUMENTS
- 8.2.3 SERVICES & SOFTWARE
- 8.3 CIRCULATING CELL-FREE DNA (CFDNA)
- 8.3.1 CONSUMABLES & ACCESSORIES
- 8.3.2 INSTRUMENTS
- 8.3.3 SERVICES & SOFTWARE
- 8.4 CELL-FREE RNA
- 8.4.1 CONSUMABLES & ACCESSORIES
- 8.4.2 INSTRUMENTS
- 8.4.3 SERVICES & SOFTWARE
- 8.5 EXOSOMES
- 8.5.1 CONSUMABLES & ACCESSORIES
- 8.5.2 INSTRUMENTS
- 8.5.3 SERVICES & SOFTWARE
- 8.6 EXTRACELLULAR VESICLES
- 8.6.1 CONSUMABLES & ACCESSORIES
- 8.6.2 INSTRUMENTS
- 8.6.3 SERVICES & SOFTWARE
- 8.7 OTHERS
9 GLOBAL LIQUID BIOPSY MARKET, BY SAMPLE TYPE
- 9.1 OVERVIEW
- 9.2 BLOOD SAMPLE-BASED
- 9.3 URINE SAMPLE-BASED
- 9.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED
- 9.5 FECAL SAMPLE BASED
- 9.6 OTHERS
-
10 GLOBAL LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE
- 10.1 OVERVIEW
- 10.2 MOLECULAR
- 10.2.1 NGS
- 10.2.2 PCR
- 10.2.3 MICROARRAY
- 10.2.4 PROTEOMICS
- 10.2.5 OTHERS
- 10.3 PROTEOMIC
- 10.3.1 NGS
- 10.3.2 PCR
- 10.3.3 MICROARRAY
- 10.3.4 PROTEOMICS
- 10.3.5 OTHERS
- 10.4 HISTOLOGY/IMAGING
11 GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION TYPE
- 11.1 OVERVIEW
- 11.2 CANCER APPLICATIONS
- 11.2.1 LUNG
- 11.2.2 BREAST
- 11.2.2.1 EARLY BREAST CANCER
- 11.2.2.1 ADVANCED BREAST CANCER
- 11.2.3 COLORECTAL
- 11.2.4 PROSTRATE
- 11.2.5 LIVER
- 11.2.6 OTHERS
- 11.3 NON-CANCER APPLICATIONS
- 11.3.1 PRENATAL DIAGNOSIS
- 11.3.2 PERSONALIZED IMMUNOTHERAPY
- 11.3.3 OTHERS
12 GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
- 12.1 OVERVIEW
- 12.2 ROUTINE SCREENING
- 12.3 THERAPY SELECTION
- 12.4 TREATMENT MONITORING
- 12.4.1 EARLY-STAGE DISEASE
- 12.4.2 LATE-STAGE/METASTATIC DISEASE
-
- 12.5 RECURRENCE MONITORING
- 12.6 PATIENT WORK-UP
- 12.7 OTHERS
13 GLOBAL LIQUID BIOPSY MARKET, BY TECHNOLOGY
- 13.1 OVERVIEW
- 13.2 MULTI-GENE-PARALLEL ANALYSIS
- 13.3 SINGLE GENE ANALYSIS
14 GLOBAL LIQUID BIOPSY MARKET, BY END USER
- 14.1 OVERVIEW
- 14.2 HOSPITALS
- 14.3 REFERENCE LABORATORIES
- 14.4 DIAGNOSTIC CENTERS
- 14.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES
- 14.6 OTHERS
15 GLOBAL LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
- 15.1 OVERVIEW
- 15.2 DIRECT TENDER
- 15.3 THIRD PARTY DISTRIBUTOR
- 15.4 OTHERS
16 GLOBAL LIQUID BIOPSY MARKET, BY REGION
- 16.1 OVERVIEW
- 16.2 NORTH AMERICA
- 16.2.1 U.S.
- 16.2.2 CANADA
- 16.2.3 MEXICO
- 16.3 EUROPE
- 16.3.1 GERMANY
- 16.3.2 FRANCE
- 16.3.3 U.K.
- 16.3.4 ITALY
- 16.3.5 SPAIN
- 16.3.6 RUSSIA
- 16.3.7 TURKEY
- 16.3.8 BELGIUM
- 16.3.9 NETHERLANDS
- 16.3.10 SWITZERLAND
- 16.3.11 REST OF EUROPE
- 16.4 ASIA-PACIFIC
- 16.4.1 JAPAN
- 16.4.2 CHINA
- 16.4.3 SOUTH KOREA
- 16.4.4 INDIA
- 16.4.5 AUSTRALIA
- 16.4.6 SINGAPORE
- 16.4.7 THAILAND
- 16.4.8 MALAYSIA
- 16.4.9 INDONESIA
- 16.4.10 PHILIPPINES
- 16.4.11 REST OF ASIA-PACIFIC
- 16.5 SOUTH AMERICA
- 16.5.1 BRAZIL
- 16.5.2 ARGENTINA
- 16.5.3 REST OF SOUTH AMERICA
- 16.6 MIDDLE EAST AND AFRICA
- 16.6.1 SOUTH AFRICA
- 16.6.2 SAUDI ARABIA
- 16.6.3 U.A.E.
- 16.6.4 EGYPT
- 16.6.5 ISRAEL
- 16.6.6 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
- 17.1 COMPANY SHARE ANALYSIS: GLOBAL
18 NORTH AMERICA LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
- 18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 EUROPE LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
- 19.1 COMPANY SHARE ANALYSIS: EUROPE
20 ASIA-PACIFIC LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
- 20.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21 COMPANY SHARE ANALYSIS BY PRODUCT
22 SWOT ANALYSIS
23 COMPANY PROFILE
- 23.1 F. HOFFMANN-LA ROCHE LTD
- 23.1.1 COMPANY SNAPSHOT
- 23.1.2 REVENUE ANALYSIS
- 23.1.3 COMPANY SHARE ANALYSIS
- 23.1.4 PRODUCT PORTFOLIO
- 23.1.5 RECENT DEVELOPMENT
- 23.2 GUARDANT HEALTH
- 23.2.1 COMPANY SNAPSHOT
- 23.2.2 REVENUE ANALYSIS
- 23.2.3 COMPANY SHARE ANALYSIS
- 23.2.4 PRODUCT PORTFOLIO
- 23.2.5 RECENT DEVELOPMENT
- 23.3 EXACT SCIENCES CORPORATION
- 23.3.1 COMPANY SNAPSHOT
- 23.3.2 REVENUE ANALYSIS
- 23.3.3 COMPANY SHARE ANALYSIS
- 23.3.4 PRODUCT PORTFOLIO
- 23.3.5 RECENT DEVELOPMENT
- 23.4 QIAGEN
- 23.4.1 COMPANY SNAPSHOT
- 23.4.2 REVENUE ANALYSIS
- 23.4.3 COMPANY SHARE ANALYSIS
- 23.4.4 PRODUCT PORTFOLIO
- 23.4.5 RECENT DEVELOPMENT
- 23.5 THERMO FISHER SCIENTIFIC INC.
- 23.5.1 COMPANY SNAPSHOT
- 23.5.2 REVENUE ANALYSIS
- 23.5.3 COMPANY SHARE ANALYSIS
- 23.5.4 PRODUCT PORTFOLIO
- 23.5.5 RECENT DEVELOPMENTS
- 23.6 ANGLE PLC (2022)
- 23.6.1 COMPANY SNAPSHOT
- 23.6.2 REVENUE ANALYSIS
- 23.6.3 PRODUCT PORTFOLIO
- 23.6.4 RECENT DEVELOPMENT
- 23.7 BIOCEPT, INC.
- 23.7.1 COMPANY SNAPSHOT
- 23.7.2 REVENUE ANALYSIS
- 23.7.3 PRODUCT PORTFOLIO
- 23.7.4 RECENT DEVELOPMENT
- 23.8 BIO-RAD LABORATORIES, INC. (2022)
- 23.8.1 COMPANY SNAPSHOT
- 23.8.2 REVENUE ANALYSIS
- 23.8.3 PRODUCT PORTFOLIO
- 23.8.4 RECENT DEVELOPMENT
- 23.9 EPIC SCIENCES
- 23.9.1 COMPANY SNAPSHOT
- 23.9.2 PRODUCT PORTFOLIO
- 23.9.3 RECENT DEVELOPMENT
- 23.10 FLUXION BIOSCIENCES INC
- 23.10.1 COMPANY SNAPSHOT
- 23.10.2 PRODUCT PORTFOLIO
- 23.10.3 RECENT DEVELOPMENT
- 23.11 ILLUMINA, INC.
- 23.11.1 COMPANY SNAPSHOT
- 23.11.2 REVENUE ANALYSIS
- 23.11.3 PRODUCT PORTFOLIO
- 23.11.4 RECENT DEVELOPMENTS
- 23.12 LABORATORY CORPORATION OF AMERICA HOLDINGS
- 23.12.1 COMPANY SNAPSHOT
- 23.12.2 REVENUE ANALYSIS
- 23.12.3 PRODUCT PORTFOLIO
- 23.12.4 RECENT DEVELOPMENT
- 23.13 MDXHEALTH
- 23.13.1 COMPANY SNAPSHOT
- 23.13.2 REVENUE ANALYSIS
- 23.13.3 PRODUCT PORTFOLIO
- 23.13.4 RECENT DEVELOPMENT
- 23.14 MENARINI SILICON BIOSYSTEMS
- 23.14.1 COMPANY SNAPSHOT
- 23.14.2 PRODUCT PORTFOLIO
- 23.14.3 RECENT DEVELOPMENT
- 23.15 NATERA, INC.
- 23.15.1 COMPANY SNAPSHOT
- 23.15.2 REVENUE ANALYSIS
- 23.15.3 PRODUCT PORTFOLIO
- 23.15.4 RECENT DEVELOPMENT
-
- 23.16 NEOGENOMICS LABORATORIES
- 23.16.1 COMPANY SNAPSHOT
- 23.16.2 REVENUE ANALYSIS
- 23.16.3 PRODUCT PORTFOLIO
- 23.16.4 RECENT DEVELOPMENT
- 23.17 ONCOCYTE CORPORATION
- 23.17.1 COMPANY PROFILE
- 23.17.2 SERVICE PORTFOLIO
- 23.17.3 RECENT DEVELOPMENT
- 23.18 PATHAI
- 23.18.1 COMPANY SNAPSHOT
- 23.18.2 PRODUCT PORTFOLIO
- 23.18.3 RECENT DEVELOPMENT
- 23.19 PREDICINE
- 23.19.1 COMPANY SNAPSHOT
- 23.19.2 PRODUCT PORTFOLIO
- 23.19.3 RECENT DEVELOPMENT
- 23.20 STRECK
- 23.20.1 COMPANY SNAPSHOT
- 23.20.2 PRODUCT PORTFOLIO
- 23.20.3 RECENT DEVELOPMENTS
- 23.21 SYSMEX INOSTICS INC. (SUBSIDIARY OF SYSMEX CORPORATION)
- 23.21.1 COMPANY SNAPSHOT
- 23.21.2 REVENUE ANALYSIS OF PARENT COMPANY
- 23.21.3 PRODUCT PORTFOLIO
- 23.21.4 RECENT DEVELOPMENT
24 QUESTIONNAIRE
25 RELATED REPORTS